Biocytogen

biocytogen.com

Biocytogen
Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

BIOCYTOGEN EXPANDS PARTNERSHIP WITH MERCK KGAA, DARMSTADT, GERMANY

Biocytogen and Merck KGaA, Darmstadt, Germany | August 26, 2022

news image

Biocytogen Pharmaceuticals Co., Ltd. entered into a global licensing agreement with Merck KGaA, Darmstadt, Germany, for the use of Biocytogen’s RenMiceTM platform. Under the terms of the agreement, Merck KGaA, Darmstadt, Germany will have full access to Biocytogen’s RenMiceTM platform to discover and develop fully human antibody therapeutics for an unlimited number of drug targets. Merck KGaA, Darmstadt, Germany will be responsible for all clinical development, manufacturing, and com...

Read More

Research, PHARMA TECH

BIOCYTOGEN ANNOUNCES NON-EXCLUSIVE LICENSE AGREEMENT WITH JANSSEN BIOTECH

Biocytogen | March 09, 2023

news image

On March 8, 2023, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen) announced a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The deal was facilitated by Johnson & Johnson Innovation LLC. Under the agreement, Janssen and its affiliates have been granted a global, non-exclusive license to utilize Biocytogen's RenLite® platform and its underlying intellectual propert...

Read More

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

news image

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More

CIVICA RX PARTNERS WITH THERMO FISHER SCIENTIFIC TO DEVELOP AND MANUFACTURE DRUGS WITH A HISTORY OF DRUG SHORTAGES

Business Wire Press Releases | January 16, 2020

news image

Today announced it has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications with Civica as the owner of the regulatory pathway. By working with Thermo Fisher to develop Civica-owned Abbreviated New Drug Applications (ANDAs), Civica will secure the manufacture of certain essential medications, further mitigating the risk of drug shortages in the future. This partnership has an initial seven-year term and represents a key component of Civica’s man...

Read More
news image

Business Insights

BIOCYTOGEN EXPANDS PARTNERSHIP WITH MERCK KGAA, DARMSTADT, GERMANY

Biocytogen and Merck KGaA, Darmstadt, Germany | August 26, 2022

Biocytogen Pharmaceuticals Co., Ltd. entered into a global licensing agreement with Merck KGaA, Darmstadt, Germany, for the use of Biocytogen’s RenMiceTM platform. Under the terms of the agreement, Merck KGaA, Darmstadt, Germany will have full access to Biocytogen’s RenMiceTM platform to discover and develop fully human antibody therapeutics for an unlimited number of drug targets. Merck KGaA, Darmstadt, Germany will be responsible for all clinical development, manufacturing, and com...

Read More
news image

Research, PHARMA TECH

BIOCYTOGEN ANNOUNCES NON-EXCLUSIVE LICENSE AGREEMENT WITH JANSSEN BIOTECH

Biocytogen | March 09, 2023

On March 8, 2023, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen) announced a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The deal was facilitated by Johnson & Johnson Innovation LLC. Under the agreement, Janssen and its affiliates have been granted a global, non-exclusive license to utilize Biocytogen's RenLite® platform and its underlying intellectual propert...

Read More
news image

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More
news image

CIVICA RX PARTNERS WITH THERMO FISHER SCIENTIFIC TO DEVELOP AND MANUFACTURE DRUGS WITH A HISTORY OF DRUG SHORTAGES

Business Wire Press Releases | January 16, 2020

Today announced it has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications with Civica as the owner of the regulatory pathway. By working with Thermo Fisher to develop Civica-owned Abbreviated New Drug Applications (ANDAs), Civica will secure the manufacture of certain essential medications, further mitigating the risk of drug shortages in the future. This partnership has an initial seven-year term and represents a key component of Civica’s man...

Read More